Oxymatrine therapy for chronic hepatitis B: A randomized double-blind and placebo-controlled multi-center trial

摘要: AIM: To evaluate the efficacy and safety of capsule oxymatrine in treatment chronic hepatitis B. METHODS: A randomised double-blind placebo-controlled multicenter trial was conducted. Injection used as positive-control drug. total 216 patients with B entered study for 24 wk, them 108 received oxymatrine, 36 injection 72 placebo. After before treatment, clinical symptoms, liver function, serum virus markers, adverse drug reaction were observed. RESULTS: Among patients, six dropped off, 11 inconsistent standard excluded. Therefore, analysed. In treated 76.47% became normal ALT level, 38.61% 31.91% negative both HBV DNA HBeAg. 83.33% 43.33% 39.29% placebo 40.00% 7.46% 6.45% The rates complete response partial 24.51% 57.84% 33.33% 50.00% 2.99% 41.79% respectively. There no significance between two groups but significantly higher than capsule, 7.77%, 6.67% 8.82%, statistically significant difference among them. CONCLUSION: Oxymatrine is an effective safe agent B.